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patterns in the mouse genome, allowing insights into the relationship of methylation with DNA
sequence, histone modifications, transcriptional activity and dynamic changes in methylation
status during differentiation.
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The past few decades have seen a revolution in the under-
standing of mechanisms of ‘epigenetic’ inheritance - the
passing on from one generation of cells to another of infor-
mation that affects phenotype but does not alter the actual
DNA sequence. One of the longest known epigenetic modifi-
cations is the methylation of cytosines in DNA, which is
typical of organisms with large genomes whose cells undergo
many divisions over the organism’s lifetime. In recent years
the realization that inappropriate methylation of promoters
of tumor suppressor genes may contribute to oncogenesis
has sparked renewed interest in DNA methylation. Despite
many years of work, however, how changes in DNA methy-
lation status occur during normal cell differentiation and
whether these changes have a role in regulating gene
expression still remain unclear. One of the few unambigu-
ously recognized facts about DNA methylation is that a
methylated promoter is highly likely to be silenced, whereas
hypomethylation of a promoter can be associated with active
or silent genes.
As with all things DNA-centric, the genomics revolution
holds great promise for understanding where cytosine
methylation occurs throughout the genome, potentially
suggesting biological function through ‘guilt by association’.
In a study published recently in Nature, Meissner et al. [1]
ally the power of massively parallel DNA sequencing to a
clever strategy for picking out GC-rich sequences from the
genome to produce the most comprehensive insight so far
into cytosine methylation at nucleotide resolution in a large
mammalian genome, that of the mouse. Such techniques will
undoubtedly increase the potential for understanding the
biological role of this venerable epigenetic regulator and its
dysregulation in disease.
C Cy yt to os si in ne e   m me et th hy yl la at ti io on n   g go oe es s   ’ ’o om mi ic c
Current assays for cytosine methylation are generally divided
into those involving protein-mediated detection and those
using chemical detection. The former allow lower-resolution
discovery studies genome-wide, a useful first pass in many
applications, whereas the latter allow nucleotide-resolution
studies but have been refractory to scaling. Only chemical
detection can provide whole-genome, single-base resolution
from individual DNA molecules. This level of resolution is
based on the deamination of cytosine, but not 5-methyl-
cytosine, to uracil by bisulphite and related compounds. In
vitro mutagenesis of DNA with bisulphite followed by
resequencing thus identifies unmethylated cytosines, as they
will have been replaced by thymines after replication of the
converted DNA. Failure to find thymine replacement is
taken as a signal that the cytosine in question was originally
the site of a 5-methylcytosine. Careful analysis of the result-
ing sequence is necessary to rule out technical artifacts, but
as almost all mammalian cytosine methylation occurs withinthe context of CG dinucleotides, non-CG cytosines serve as
useful controls for conversion of unmethylated Cs.
Two types of bisulphite assays have been used, exploring
what we call intermolecular and intramolecular dimensions.
By intermolecular, we mean the overall frequency of methy-
lation at a given CG across a population of molecules,
whereas by intramolecular we mean the coordinate methy-
lation patterns of different CGs located in cis on the same
molecule. The short read lengths of the study by Meissner et
al. [1] limit the ability to detect intramolecular information,
although given evidence of correlation between CGs located
up to 1 kb in cis in the human genome [2] this may not prove
a great loss. On the other hand, intermolecular information
is determined by read number per cytosine, and these data
are valuable when allelic methylation is being studied, such
as in genomic imprinting (for a review see [3]), and can
indicate heterogeneity of methylation occurring in different
cells in the population being studied. In any case, we note
that the ideal assay to explore both dimensions of
nucleotide-resolution bisulphite sequence would be one with
deep coverage consisting of long cis read information.
Such a platform does not yet exist, but significant insights
have been obtained into the relatively small Arabidopsis
thaliana genome using massively parallel sequencing of
bisulphite-converted DNA on a short-read platform (from
Illumina) [4]. The substantially greater size of the human
genome makes a comparable approach daunting, especially
in analyzing the data. In large part, this is because after
bisulphite conversion, the four-base ‘native’ genome is effec-
tively collapsed into a three-base genome, with the original
Cs remaining on only some CG dinucleotides. Worse, the
strands of the genome are no longer complementary, so the
effective size of the converted genome doubles, making
sequence mapping to 6 Gb converted mammalian genomes a
serious challenge. The study of Meissner et al. [1] partly gets
round this problem by using a clever strategy of ‘reduced-
representation bisulphite sequencing’.
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Meissner et al. extend previous work from the same group
[5] which used Sanger sequencing on a restriction-enzyme-
based sampling of the genome. In the new work, reduced
representation of the genome was achieved by the isolation of
small restriction fragments generated by the methylation-
insensitive type II endonuclease MspI, resulting in
enrichment of CG-rich regions, and thereby directing the
analysis towards CpG islands and less to CG-depleted regions
of the genome. This enabled comprehensive sequencing of this
fraction and easier mapping of the bisulphite-converted
sequences onto this more limited search space. Moreover,
because of the imposed directionality of the sequencing
adaptors, there was only one strand to analyze, further
simplifying the mapping problem at the expense of identifying
instances of hemimethylation - a relatively small price to
pay. Only around 1% of the genome was sampled in this
study, however, which leaves the remaining 99% of potential
methylation space unexplored.
Analysis of the sequencing data was designed to ensure that
only reads with unique alignments to the reference mouse
genome were picked up. This involved mapping the sequence
data to a simulated bisulphite-converted unmethylated
genome, converting any remaining Cs in the sequence reads
to Ts for initial alignment, and eliminating reads with more
than one map position. Once mapped, the original Cs were
recalled to the analysis, counting the frequency at which Cs
and Ts were located at the same position across reads, and
thus inferring the methylation status. To avoid including
sequencing errors, quality scores for sequencing base calls
were utilized as a data filter, ignoring low-quality bases at
potential methylation sites, an important advance on
previous studies [6,7].
Bisulphite genomic representations have traditionally demon-
strated bias in genomic coverage, but recent observations
suggest that by avoiding a step of cloning in bacteria, current
massively parallel sequencing protocols have avoided such
bias, although this should be determined empirically for
each platform. Any detected distortion of representation
and/or coverage at a CG site when comparing native and
bisulphite-converted spaces could be used to adjust the
inferred DNA methylation levels from those regions of the
genome. Another useful in silico experiment would be to
assess the impact of random data assembly within the
representation space. An assessment of the contribution of
random data to the inferred methylation levels would allow
this artifact to be accounted for analytically in a region-
specific manner. Finally, a future analytical goal should be to
modify the match matrices used for alignment scoring.
Mapping reads to a native genome using a penalty matrix
tolerant to the bisulphite-induced SNPs in the reads should
allow more accurate positioning of reads and identification
of sample-specific SNPs to extract optimum-quality
methylation data. Certainly, moving to larger endeavors
(such as the whole genome) will require such fundamental
approaches to be optimized. The study by Meissner et al. [1]
sets the stage and serves as a compass for future efforts.
Encouragingly, their platform’s ability to measure genomic
methylation was demonstrated through the convincing
detection of biologically significant variation occurring with
cell differentiation.
I In ns si ig gh ht ts s   i in nt to o   t th he e   b bi io ol lo og gi ic ca al l   s si ig gn ni if fi ic ca an nc ce e   o of f   c cy yt to os si in ne e
m me et th hy yl la at ti io on n
Meissner et al. had two major biological aims: to look first at
static relationships of cytosine methylation with DNA
sequence features and histone modifications in embryonic
stem (ES) cells; and then to test the dynamic properties of
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case, their analysis largely confirmed previous findings, with
transposable elements consistently methylated and a strong
correlation between CG density and hypomethylation. How-
ever, not all transposable elements behaved the same way -
autonomously transposing long interspersed nuclear elements
(LINEs)  and long terminal repeat (LTR) elements were
methylated whatever their CG content, whereas the more CG-
rich subgroup of non-autonomous short interspersed nuclear
elements (SINEs) were generally unmethylated and looked
comparable to nonrepetitive DNA of similar CG content.
Correlation of cytosine methylation with histone-modifica-
tion patterns was confirmed, with results suggesting that
histone H3 lysine 4 and lysine 9 methylation are better
predictors of cytosine methylation than CG content,
although trimethylation of lysine 27 on H3 did not have the
same predictive power. The last finding is interesting, as
biochemical studies have found the enzyme responsible for
methylating lysine 27 (the Polycomb group protein EZH2) to
be in a complex with DNA methyltransferases [8], suggest-
ing that both these repressive marks - trimethylated H3K27
and methylated cytosines - might have been coincident in
the genome. Interestingly, CG-depleted non-promoter regions
enriched in H3 lysine 4 dimethylation displayed a greater
tendency for the DNA to be unmethylated, suggesting that
the cell generally marks regulatory elements with DNA
hypomethylation, an idea first proposed by Adrian Bird (for
review see [9]).
A question that arises when considering cytosine methy-
lation mapping studies is how and why methylation is
directed to some sequences and not others. Much has been
learned from the study of methylation mutants in the mouse
and Arabidopsis [10-12]. Cytosine methylation is catalyzed
by a family of DNA methyltransferases that do not have
innate sequence specificity, with one recognized exception,
the Dnmt3a-Dnmt3L complex, which appears to process
CGs spaced apart by 8-10 bp (a single helical turn) more
efficiently [13]. Demethylation may occur either passively -
by failure to remethylate after replication - or actively by
demethylase activity: potential demethylases might include
glycosylase [14] or base excision activity [15] replacing the
methylcytosine with cytosine, and even by mutagenic
deamination mediated by DNA methyltransferases [16],
although this field is not free from controversy [17]. The
correlation between histone modifications and DNA methy-
lation supports ideas that methylation may be targeted by
pre-existing signals such as histone modification [18], or
that both histone modification and cytosine methylation
could be directed by sequence-specific molecules such as
transcription factors or even small RNAs (for a review see
[19]). However, one observation suggests that we are still
missing part of the mechanism for establishing and
maintaining the methylation pattern. In both the mouse and
Arabidopsis, DNA left unmethylated as a result of mutation
of DNA methyltransferase will become remethylated on
reintroduction of the enzyme, but such remethylation occurs
much more slowly in the absence of the SWI/SNF main-
tenance factor DDM1/LSH1 [11,20-22].
The advent of see-it-all ’omics has reopened investigation
into the role of cytosine methylation in cellular differen-
tiation - a controversial topic. There are clear differences in
cytosine methylation between distinct cell types [23], but
many promoters are constitutively hypomethylated even
when the gene is transcriptionally silent [24]. Meissner et al.
[1] addressed this issue by differentiating ES cells to neural
lineages in culture and retesting the same loci for cytosine
methylation. They found that CG-dense regions remained
hypomethylated for the most part, whereas CG-depleted
regions were more likely to change DNA methylation status
with differentiation. The so-called ‘bivalent chromatin
domains’ first described in ES cells [25] tended to remain
constitutively cytosine hypomethylated. The authors also
compared  in-vivo-derived, minimally cultured neural
precursor cells (NPCs) with NPCs derived in vitro, revealing
substantially less methylation in the primary cells. However,
multiple passaging of the in-vivo-derived NPCs resulted in
methylation patterns comparable with the ES-cell-derived
NPCs, implicating cell culture in the generation of these
‘epialleles’. Intriguingly, a specific subset of CG-dense
promoters tended to be more consistently susceptible to this
acquisition of methylation, an observation paralleling
changes observed in cancer cells [26]. The effect of tissue
culture on the variability of cytosine methylation has been
recognized for some time [27]; the current study points to a
similar phenomenon and was able to test far more CGs than
previously possible. The obvious question is whether
chromatin modifications, which are shown to be correlated
with cytosine methylation, are also influenced by cell culture
or whether this is an observation specifically affecting
cytosine methylation.
The study by Meissner et al. represents a breakthrough in the
ability to study cytosine methylation in mammalian cells, an
advance that is directly due to the introduction of massively
parallel sequencing technologies, coupled with a clever
experimental design that allowed comprehensive sequencing
of CpG islands and mapping of degenerate sequences to the
genome. With longer reads, intramolecular cytosine methy-
lation could be explored more comprehensively, and increased
sequencing throughput should some day make whole-
genome methylation studies feasible for genomes as large as
those of mouse and human. Meissner et al. note the potential
for increasing genomic coverage by adding further restriction
enzyme representations or by coupling massively parallel
bisulphite sequencing with the sequence-capture approach
[28]. With these and other advances, the potential for
revealing how cytosine methylation exerts its effects in
normal cells will be immense, forming the basis for under-
standing the changes that we see in human disease.
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